Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odronextamab + zanubrutinib
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Odronextamab + zanubrutinib is a combination therapy being investigated for the treatment of Richter's transformation (RT). Odronextamab (Ordspono) is a bispecific monoclonal antibody that targets CD20 on B cells and CD3 on T cells, facilitating T-cell mediated destruction of malignant B cells. Zanubrutinib (Brukinsa) is a potent, selective, and irreversible small-molecule inhibitor of Bruton tyrosine kinase (BTK), which plays a crucial role in B-cell receptor signaling. The combination is currently being evaluated in a Phase I clinical trial led by City of Hope Medical Center to assess its safety and efficacy in patients with RT, a rare and aggressive transformation of chronic lymphocytic leukemia into high-grade lymphoma. This therapeutic approach aims to leverage both direct B-cell receptor pathway inhibition and immune-mediated cytotoxicity to overcome the aggressive nature of transformed lymphoma.
- Brand names
- OrdsponoBrukinsa
- Other names
- odronextamab and zanubrutinib
02
Targets
Beyond the preview
Go deeper on odronextamab + zanubrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odronextamab + zanubrutinib.